Exhibit 32.1
SECTION 1350 CERTIFICATIONS*
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), Howard W. Robin, Chief Executive Officer, President and Director of Nektar Therapeutics (the “Company”), and Sandra Gardiner, Interim Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:
Dated: March 5, 2024
/s/ HOWARD W. ROBIN | /s/ Sandra Gardiner | |
Howard W. Robin |
| Sandra Gardiner |
Chief Executive Officer, President and Director | Interim Chief Financial Officer | |
|
|
|